Isabelle Mourand1, Mehdi Mahmoudi2, Emmanuelle Lebars2, Frederique Pavillard3, Cyril Dargazanli2, Julien Labreuche4, Nicolas Gaillard5, Adrien Ter Schiphorst5, Imad Derraz2, Denis Sablot6, Lucas Corti5, Vincent Costalat2, Caroline Arquizan5, Federico Cagnazzo2. 1. Neurology Department, Centre Hospitalier Universitaire, Hôpital Gui de Chauliac, 80 avenue Augustin Fliche, 34295, Montpellier, France. i-mourand@chu-montpellier.fr. 2. Neuroradiology Department, Centre Hospitalier Universitaire, Montpellier, France. 3. Department of Reanimation, Centre Hospitalier Universitaire, Montpellier, France. 4. Biostatistics department, Centre Hospitalier Universitaire, Lille, France. 5. Neurology Department, Centre Hospitalier Universitaire, Hôpital Gui de Chauliac, 80 avenue Augustin Fliche, 34295, Montpellier, France. 6. Neurology department, Centre Hospitalier, Perpignan, France.
Abstract
PURPOSE: The relationship between posterior-circulation lesion volume (PCLV) and clinical outcomes is poorly investigated. We aimed to analyze, in patients with acute basilar artery occlusion (ABAO), if pre-endovascular treatment (EVT) PCLV was a predictor of outcomes. METHODS: We analyzed consecutive MRI selected, endovascularly treated ABAO patients. Baseline PCLV was measured in milliliters on apparent diffusion-coefficient map reconstruction. Univariable and multivariable logistic models were used to test if PCLV was a predictor of 90-day outcomes. After the received operating characteristic (ROC) analysis, the optimal cut-off was determined to evaluate the prognostic value of PCLV. RESULTS: A total of 110 ABAO patients were included. The median PCLV was 4.4 ml (interquartile range, 1.3-21.2 ml). Successful reperfusion was achieved in 81.8% of cases after EVT. At 90 days, 31.8% of patients had a modified Rankin scale ≤ 2, and the mortality rate was 40.9%. PCLV was an independent predictor of functional independence and mortality (odds ratio [OR]:0.57, 95% confidence interval [CI], 0.34-0.93 and 1.84, 95% CI, 1.23-2.76, respectively). The ROC analysis showed that a baseline PCLV ≤ 8.7 ml was the optimal cut-off to predict the 90-day functional independence (area under the curve [AUC] = 0.68, 95% CI, 0.57-0.79, sensitivity 88.6%, and specificity 49.3%). In addition, a PCLV ≥ 9.1 ml was the optimal cut-off for the prediction of 90-day mortality (AUC = 0.71, 95% CI, 0.61-0.82, sensitivity 80%, and specificity 60%). CONCLUSIONS: Pre-treatment PCLV was an independent predictor of 90-day outcomes in ABAO. A PCLV ≤ 8.7 and ≥ 9.1 ml may identify patients with a higher possibility to achieve independence and a higher risk of death at 90 days, respectively.
PURPOSE: The relationship between posterior-circulation lesion volume (PCLV) and clinical outcomes is poorly investigated. We aimed to analyze, in patients with acute basilar artery occlusion (ABAO), if pre-endovascular treatment (EVT) PCLV was a predictor of outcomes. METHODS: We analyzed consecutive MRI selected, endovascularly treated ABAO patients. Baseline PCLV was measured in milliliters on apparent diffusion-coefficient map reconstruction. Univariable and multivariable logistic models were used to test if PCLV was a predictor of 90-day outcomes. After the received operating characteristic (ROC) analysis, the optimal cut-off was determined to evaluate the prognostic value of PCLV. RESULTS: A total of 110 ABAO patients were included. The median PCLV was 4.4 ml (interquartile range, 1.3-21.2 ml). Successful reperfusion was achieved in 81.8% of cases after EVT. At 90 days, 31.8% of patients had a modified Rankin scale ≤ 2, and the mortality rate was 40.9%. PCLV was an independent predictor of functional independence and mortality (odds ratio [OR]:0.57, 95% confidence interval [CI], 0.34-0.93 and 1.84, 95% CI, 1.23-2.76, respectively). The ROC analysis showed that a baseline PCLV ≤ 8.7 ml was the optimal cut-off to predict the 90-day functional independence (area under the curve [AUC] = 0.68, 95% CI, 0.57-0.79, sensitivity 88.6%, and specificity 49.3%). In addition, a PCLV ≥ 9.1 ml was the optimal cut-off for the prediction of 90-day mortality (AUC = 0.71, 95% CI, 0.61-0.82, sensitivity 80%, and specificity 60%). CONCLUSIONS: Pre-treatment PCLV was an independent predictor of 90-day outcomes in ABAO. A PCLV ≤ 8.7 and ≥ 9.1 ml may identify patients with a higher possibility to achieve independence and a higher risk of death at 90 days, respectively.
Authors: M Möhlenbruch; S Stampfl; L Behrens; C Herweh; S Rohde; M Bendszus; C Hametner; S Nagel; P A Ringleb; M Pham Journal: AJNR Am J Neuroradiol Date: 2013-11-28 Impact factor: 3.825
Authors: Alexander Karameshev; Marcel Arnold; Gerhard Schroth; Liliane Kappeler; Paul Stein; Jan Gralla; Caspar Brekenfeld; Oliver Findling; Marie-Luise Mono; Gian Marco De Marchis; Urs Fischer; Heinrich P Mattle; Krassen Nedeltchev; Marwan El-Koussy Journal: Cerebrovasc Dis Date: 2011-10-08 Impact factor: 2.762
Authors: Lucianne C M Langezaal; Erik J R J van der Hoeven; Francisco J A Mont'Alverne; João J F de Carvalho; Fabrício O Lima; Diederik W J Dippel; Aad van der Lugt; Rob T H Lo; Jelis Boiten; Geert J Lycklama À Nijeholt; Julie Staals; Wim H van Zwam; Paul J Nederkoorn; Charles B L M Majoie; Johannes C Gerber; Mikael Mazighi; Michel Piotin; Andrea Zini; Stefano Vallone; Jeannette Hofmeijer; Sheila O Martins; Christian H Nolte; Kristina Szabo; Francisco A Dias; Daniel G Abud; Marieke J H Wermer; Michel J M Remmers; Hauke Schneider; Christina M Rueckert; Karlijn F de Laat; Albert J Yoo; Pieter-Jan van Doormaal; Adriaan C G M van Es; Bart J Emmer; Patrik Michel; Volker Puetz; Heinrich J Audebert; Octavio M Pontes-Neto; Jan-Albert Vos; L Jaap Kappelle; Ale Algra; Wouter J Schonewille Journal: N Engl J Med Date: 2021-05-20 Impact factor: 91.245
Authors: Simon Nagel; Christian Herweh; Martin Köhrmann; Hagen B Huttner; Sven Poli; Marius Hartmann; Stefan Hähnel; Thorsten Steiner; Peter Ringleb; Werner Hacke Journal: Int J Stroke Date: 2011-12-08 Impact factor: 5.266
Authors: I Mourand; P Machi; E Nogué; C Arquizan; V Costalat; M-C Picot; A Bonafé; D Milhaud Journal: AJNR Am J Neuroradiol Date: 2014-02-13 Impact factor: 3.825
Authors: M Mahmoudi; C Dargazanli; F Cagnazzo; I Derraz; C Arquizan; A Wacogne; J Labreuche; A Bonafe; D Sablot; P H Lefevre; G Gascou; N Gaillard; C Scott; V Costalat; I Mourand Journal: AJNR Am J Neuroradiol Date: 2020-08-20 Impact factor: 3.825